Whitefort Capital Management, LP, the third largest shareholder of Arbutus Biopharma Corp. (ABUS) with an ownership interest of approximately 6.8% of the company's outstanding shares, issued a letter to Arbutus Biopharma's Board outlining its views the company must take in order to maximize shareholder value. Also, Whitefort Capital formally requested a meeting with the full Board in the coming weeks to ensure that there is full alignment of views regarding the path forward for the company.
"We look forward to the company engaging now and over the next few quarters in strategic partnership discussions regarding its HBV program and urge the Company to make a public announcement committing to no dilutive equity issuances or ATM use for another year," said Whitefort Capital.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.